BR112022002496A2 - Compostos deuterados para uso no tratamento de câncer - Google Patents

Compostos deuterados para uso no tratamento de câncer

Info

Publication number
BR112022002496A2
BR112022002496A2 BR112022002496A BR112022002496A BR112022002496A2 BR 112022002496 A2 BR112022002496 A2 BR 112022002496A2 BR 112022002496 A BR112022002496 A BR 112022002496A BR 112022002496 A BR112022002496 A BR 112022002496A BR 112022002496 A2 BR112022002496 A2 BR 112022002496A2
Authority
BR
Brazil
Prior art keywords
cancer
treatment
deuterated compounds
deuterated
compounds
Prior art date
Application number
BR112022002496A
Other languages
English (en)
Inventor
Harry Finch
Hollie Mccarron
Mark Charles
Martin Stockley
Peter Blencowe
Robert Heald
Tennyson Ekwuru
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2019/052240 external-priority patent/WO2021028643A1/en
Priority claimed from GBGB1917863.1A external-priority patent/GB201917863D0/en
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Publication of BR112022002496A2 publication Critical patent/BR112022002496A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos deuterados para uso no tratamento de câncer. a invenção se refere a derivados de amida deuterados da fórmula (i) e seu uso no tratamento e na profilaxia de câncer, e a composições contendo os ditos derivados e processos para sua preparação.
BR112022002496A 2019-08-09 2020-08-10 Compostos deuterados para uso no tratamento de câncer BR112022002496A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2019/052240 WO2021028643A1 (en) 2019-08-09 2019-08-09 Heterocyclic compounds for use in the treatment of cancer
GBGB1917863.1A GB201917863D0 (en) 2019-12-06 2019-12-06 Novel compounds
PCT/GB2020/051901 WO2021028670A1 (en) 2019-08-09 2020-08-10 Deuterated compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112022002496A2 true BR112022002496A2 (pt) 2022-04-26

Family

ID=72039615

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002496A BR112022002496A2 (pt) 2019-08-09 2020-08-10 Compostos deuterados para uso no tratamento de câncer

Country Status (23)

Country Link
US (1) US20220259174A1 (pt)
EP (1) EP4010329B9 (pt)
JP (1) JP2022544211A (pt)
KR (1) KR20220050148A (pt)
CN (1) CN114846003A (pt)
AU (1) AU2020327661A1 (pt)
BR (1) BR112022002496A2 (pt)
CA (1) CA3149119A1 (pt)
DK (1) DK4010329T3 (pt)
ES (1) ES2952281T3 (pt)
FI (1) FI4010329T3 (pt)
HR (1) HRP20231037T1 (pt)
HU (1) HUE063145T2 (pt)
IL (1) IL290415A (pt)
LT (1) LT4010329T (pt)
MX (1) MX2022001690A (pt)
PL (1) PL4010329T3 (pt)
PT (1) PT4010329T (pt)
RS (1) RS64486B1 (pt)
SI (1) SI4010329T1 (pt)
TW (1) TW202120486A (pt)
WO (1) WO2021028670A1 (pt)
ZA (1) ZA202201364B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022216878A1 (en) * 2021-02-07 2023-08-17 Artios Pharma Limited Novel process
WO2023125841A1 (zh) * 2021-12-29 2023-07-06 武汉人福创新药物研发中心有限公司 作为Polθ抑制剂的杂环化合物及其制备方法和用途
WO2023125918A1 (zh) * 2021-12-30 2023-07-06 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
TW202341998A (zh) * 2022-03-10 2023-11-01 大陸商四川海思科製藥有限公司 DNA聚合酶θ抑制劑及其用途
WO2023169573A1 (zh) * 2022-03-11 2023-09-14 武汉人福创新药物研发中心有限公司 一种Polθ抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CA2860858A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
CN107556366A (zh) * 2016-06-30 2018-01-09 上海海和药物研究开发有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途

Also Published As

Publication number Publication date
EP4010329A1 (en) 2022-06-15
EP4010329B9 (en) 2023-10-04
AU2020327661A1 (en) 2022-02-24
RS64486B1 (sr) 2023-09-29
MX2022001690A (es) 2022-05-10
US20220259174A1 (en) 2022-08-18
TW202120486A (zh) 2021-06-01
CA3149119A1 (en) 2021-02-18
LT4010329T (lt) 2023-09-11
ZA202201364B (en) 2023-11-29
IL290415A (en) 2022-04-01
HRP20231037T1 (hr) 2023-12-08
EP4010329B1 (en) 2023-06-07
PL4010329T3 (pl) 2023-10-16
ES2952281T3 (es) 2023-10-30
PT4010329T (pt) 2023-08-18
CN114846003A (zh) 2022-08-02
WO2021028670A1 (en) 2021-02-18
JP2022544211A (ja) 2022-10-17
FI4010329T3 (fi) 2023-08-30
KR20220050148A (ko) 2022-04-22
DK4010329T3 (da) 2023-09-04
HUE063145T2 (hu) 2023-12-28
SI4010329T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
BR112015027527A2 (pt) intensificador de inibidores do homólogo zeste 2
DOP2018000241A (es) Derivados aromáticos de sulfonamida
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112017008840A2 (pt) intensificador de inibidores do homólogo 2 de zeste
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
BR112018070448A2 (pt) derivados de aminotiazol úteis como agentes antivirais
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento
CO2021004553A2 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112021020405A2 (pt) Benzo- e pirido-pirazóis como inibidores de proteína quinase
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
MX2023004955A (es) Compuestos de aminotiazol deuterados como compuestos antiviricos.
CL2021000282A1 (es) Inhibidores de ckd8/19
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
BR112021025877A2 (pt) Derivados de amina terciária e seus usos para tratar uma infecção viral
EA202191588A1 (ru) Замещенные ксантиновые производные